Literature DB >> 26149894

Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C.

Yehuda Z Cohen1, Christy L Lavine1, Caroline A Miller1, Jetta Garrity1, Brittany R Carey1, Michael S Seaman1.   

Abstract

A number of potent broadly neutralizing antibodies against HIV-1 have recently been identified that target epitopes on the viral envelope that contain N-linked glycans. It remains unknown how frequently glycan-dependent neutralizing antibodies generally arise during the course of natural infection or whether particular glycosylation sites are preferentially targeted. We tested sera with a broad range of neutralization activity from individuals infected with HIV-1 clades B or C against panels of HIV-1Env pseudoviruses that lacked specific glycans in the outer domain glycan cluster (ODGC) or inner domain glycan cluster (IDGC) to determine the presence of glycan-dependent neutralizing antibodies. Overall, 54% of individuals were observed to have neutralizing antibodies targeting these glycan regions. Glycan-specific neutralizing antibodies were readily detected in sera that were selected for having broad, moderate, or weak neutralization potency and breadth. Our results demonstrate that glycan-specific neutralizing antibodies arise with appreciable frequency in individuals chronically infected with HIV-1 clades B and C. Antibody responses that commonly occur during natural infection may be more feasible to induce by vaccination; thus glycan-specific neutralizing antibodies may be desirable responses to elicit with candidate HIV-1 vaccines.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26149894      PMCID: PMC4651021          DOI: 10.1089/AID.2015.0135

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  48 in total

Review 1.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

2.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

3.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

4.  Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

Authors:  Marcella Sarzotti-Kelsoe; Robert T Bailer; Ellen Turk; Chen-li Lin; Miroslawa Bilska; Kelli M Greene; Hongmei Gao; Christopher A Todd; Daniel A Ozaki; Michael S Seaman; John R Mascola; David C Montefiori
Journal:  J Immunol Methods       Date:  2013-12-01       Impact factor: 2.303

5.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

6.  Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.

Authors:  David C Montefiori
Journal:  Curr Protoc Immunol       Date:  2005-01

7.  Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Authors:  Penny L Moore; Elin S Gray; C Kurt Wibmer; Jinal N Bhiman; Molati Nonyane; Daniel J Sheward; Tandile Hermanus; Shringkhala Bajimaya; Nancy L Tumba; Melissa-Rose Abrahams; Bronwen E Lambson; Nthabeleng Ranchobe; Lihua Ping; Nobubelo Ngandu; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald I Swanstrom; Michael S Seaman; Carolyn Williamson; Lynn Morris
Journal:  Nat Med       Date:  2012-10-21       Impact factor: 53.440

8.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962

9.  Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Authors:  Constantinos Kurt Wibmer; Jinal N Bhiman; Elin S Gray; Nancy Tumba; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris; Penny L Moore
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

10.  Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer.

Authors:  Ronald Derking; Gabriel Ozorowski; Kwinten Sliepen; Anila Yasmeen; Albert Cupo; Jonathan L Torres; Jean-Philippe Julien; Jeong Hyun Lee; Thijs van Montfort; Steven W de Taeye; Mark Connors; Dennis R Burton; Ian A Wilson; Per-Johan Klasse; Andrew B Ward; John P Moore; Rogier W Sanders
Journal:  PLoS Pathog       Date:  2015-03-25       Impact factor: 6.823

View more
  2 in total

1.  Deep mutagenesis in the study of COVID-19: a technical overview for the proteomics community.

Authors:  Erik Procko
Journal:  Expert Rev Proteomics       Date:  2020-10-21       Impact factor: 3.940

Review 2.  Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities.

Authors:  Anna Timofeeva; Sergey Sedykh; Georgy Nevinsky
Journal:  Vaccines (Basel)       Date:  2022-03-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.